June 20, 2025 10:17 AM EDT
Financing
Startups

Ear­ly-stage in­vestor Syn­cona read­justs pri­or­i­ties due to bleak biotech mar­ket

Max Gelman

Senior Editor

The des­o­late biotech fi­nanc­ing en­vi­ron­ment is start­ing to take a toll on in­vest­ment funds, with the UK life sci­ences firm Syn­cona an­nounc­ing it is re­align­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

Phar­ma com­pa­nies are weigh­ing how a drug’s IP lo­ca­tion could im­pact tar­iffs

In­side the FDA’s ‘lis­ten­ing’ tour: Of­fi­cials agree US lags be­hind Chi­na on drug de­vel­op­ment

Roche's ven­ture arm chief to step down in 2026; As­traZeneca obe­si­ty leader has re­tired

UK's NICE says Lil­ly, Ei­sai's Alzheimer's drugs aren't worth na­tion­al cov­er­age

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times